ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
내장통 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 연평균 5.9%의 CAGR로 187억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 통증 관리의 기술 혁신, 비침습적 치료 옵션에 대한 수요 증가, 신흥 시장 및 미개척 기회, 개인화된 의료 접근법, 디지털 헬스 솔루션의 통합 등에 기인하는 것으로 분석됩니다. 예측 기간 동안 주요 동향으로는 다중 방법을 통한 통증 관리로의 전환, 대체 요법에 대한 관심 증가, 특정 통증 유형에 대한 표적 치료의 부상, 통증 관리에서 원격의료의 역할 증대, 통증 평가에 인공지능의 통합 등이 있습니다.
진통제에 대한 수요 증가가 향후 내장통증 치료제 시장 확대를 견인할 것으로 예상됩니다. 진통제는 통증 신호에 대한 뇌의 인식을 감소시키거나 차단하여 통증을 완화하는 약물입니다. 이들 약물은 신경계에 작용하여 내장으로부터의 통증 신호를 조절함으로써 내장통 관리에 도움을 주고 있습니다. 예를 들어, 2024년 4월 영국의 주간 의학잡지 New England Journal of Medicine은 2023년 12월까지 53,600명 이상의 임상의가 부프레노르핀을 처방했으며, 2022년 12월에 비해 11,500명이 처방이 증가했다고 보고했습니다. 이처럼 진통제에 대한 수요 증가가 내장통 시장의 성장을 견인하고 있습니다.
내장통 시장의 주요 기업들은 NHE3 억제제와 같은 혁신적인 제품 개발에 전념하여 소비자에게 신뢰할 수 있는 솔루션을 제공하고 있으며, NHE3 억제제는 소화관 내 나트륨-양성자 교환기 아형 3(NHE3)을 억제하여 작용하는 의약품 그룹을 구성합니다. 예를 들어, 2022년 4월 미국 바이오 제약사 아델릭스(Arderix)는 IBSRELA라는 NHE3 억제제를 발표했습니다. 이 획기적인 치료제는 변비를 동반한 과민성대장증후군(IBS-C)을 앓고 있는 성인을 대상으로 소장과 대장의 나트륨-수소 교환체 3(NHE3)에 작용합니다. 전임상시험에서 내장 과민성 및 장 투과성을 완화하여 복통을 감소시키는 효과가 입증되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 내장통 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
최종 이용 산업 분석
세계의 내장통 시장 : 성장률 분석
세계의 내장통 시장 실적 : 규모와 성장, 2019-2024
세계의 내장통 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 내장통 전체 시장(TAM)
제6장 시장 세분화
세계의 내장통 시장 : 약물 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
칼슘 채널 차단제
비스테로이드성 항염증제(NSAID)
기타 약물 클래스
세계의 내장통 시장 : 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
간질성 방광염
크론병
과민성대장증후군
만성 전립선염
기타 적응증
세계의 내장통 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
홈케어
전문 클리닉
기타 최종사용자
세계의 내장통 시장, 칼슘 채널 차단제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
디하이드로피리딘
비디하이드로피리딘
세계의 내장통 시장, 비스테로이드성 항염증제(NSAID) 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
선택적 COX-2 억제제
비선택적 NSAID
세계의 내장통 시장, 기타 약물 클래스 유형별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
오피오이드
삼환계 항우울제(TCA)
세로토닌·노르에피네프린 재흡수 억제제(SNRI)
제7장 지역별·국가별 분석
세계의 내장통 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 내장통 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
내장통 시장 : 경쟁 구도
내장통 시장 : 기업 개요
Walgreens Boots Alliance Inc. Overview, Products and Services, Strategy and Financial Analysis
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
AbbVie Inc.
Novartis AG
Sanofi SA
Bristol-Myers Squibb Company
AstraZeneca PLC
GlaxoSmithKline PLC
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
Bausch Health Companies Inc.
Sun Pharmaceutical Industries Ltd.
Perrigo Company PLC
Dr. Reddy's Laboratories Ltd.
Endo International PLC
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
내장통 시장 2029 : 새로운 기회를 제공하는 국가
내장통 시장 2029 : 새로운 기회를 제공하는 부문
내장통 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Visceral pain originates from internal organs such as the stomach, bladder, uterus, or rectum and can stem from factors such as inflammation, menstrual cramps, organ swelling, blockages, reduced blood flow, or tumors, particularly in the pelvis or abdomen, often accompanied by symptoms such as nausea, sweating, or increased heart rate.
The principal drug classes for treating visceral pain include calcium channel blockers (CCBs), nonsteroidal anti-inflammatories (NSAIDs), and others. CCBs regulate calcium ion movement into heart and blood vessel cells, with indications spanning interstitial cystitis, Crohn's disease, irritable bowel syndrome, chronic prostatitis, and more. These medications are employed across various end-user settings including hospitals, homecare, specialty clinics, among others.
The visceral pain market research report is one of a series of new reports from The Business Research Company that provides visceral pain market statistics, including visceral pain industry global market size, regional shares, competitors with a visceral pain market share, detailed visceral pain market segments, market trends, and opportunities, and any further data you may need to thrive in the visceral pain industry. This visceral pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The visceral pain market size has grown strongly in recent years. It will grow from $13.84 billion in 2024 to $14.87 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to aging population, increased incidence of chronic diseases, advances in medical research, expansion of healthcare infrastructure, rising awareness and diagnosis rates.
The visceral pain market size is expected to see strong growth in the next few years. It will grow to $18.71 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to technological innovations in pain management, growing demand for non-invasive treatment options, emerging markets and untapped opportunities, personalized medicine approaches, integration of digital health solutions. Major trends in the forecast period include shift towards multimodal pain management, increasing emphasis on alternative therapies, rise of targeted therapies for specific pain types, growing role of telemedicine in pain management, integration of artificial intelligence in pain assessment.
The growing demand for analgesics is anticipated to drive the expansion of the visceral pain market in the future. Analgesics are medications that relieve pain by reducing or blocking the brain's perception of pain signals. These medications help manage visceral pain by acting on the nervous system to modulate pain signals from internal organs. For example, in April 2024, the New England Journal of Medicine, a UK-based weekly medical journal, reported that over 53,600 clinicians were prescribing buprenorphine by December 2023, marking an increase of 11,500 prescribers compared to December 2022. Thus, the rising demand for analgesics is fueling the growth of the visceral pain market.
Prominent companies in the visceral pain market are dedicated to developing innovative products such as NHE3 Inhibitors to offer dependable solutions to consumers. NHE3 inhibitors constitute a class of medications that function by inhibiting the Sodium-Proton-Exchanger subtype 3 (NHE3) in the gastrointestinal tract. For example, in April 2022, Ardelyx, a US-based biopharmaceutical firm, introduced an NHE3 Inhibitor medication called IBSRELA. This groundbreaking treatment targets adults with irritable bowel syndrome with constipation (IBS-C), acting on the Sodium-Hydrogen Exchanger 3 (NHE3) in the small intestine and colon. Preclinical studies have demonstrated its efficacy in reducing abdominal pain by alleviating visceral hypersensitivity and intestinal permeability.
In April 2023, Marksans Pharma, a pharmaceutical company based in India, acquired Teva Pharmaceuticals' manufacturing facility in India for an undisclosed amount. This acquisition provides Marksans with a 47,597-square-meter facility, allowing it to double its production capacity in India from 8 billion units per year. The increased capacity will facilitate the production of tablets, hard and soft gel capsules, ointments, liquids, and creams. Teva Pharmaceuticals is an Israel-based company that provides treatments for visceral pain.
Major companies operating in the visceral pain market report are Walgreens Boots Alliance Inc., Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co.Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Endo International PLC, Grunenthal GmbH, Glenmark Pharmaceuticals Limited, Hisamitsu Pharmaceutical Co. Ltd., Chromocell Corporation, Addex Therapeutics Ltd.
North America was the largest region in the visceral pain market in 2024. The regions covered in the visceral pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the visceral pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The visceral pain market consists of sales of opioids, anticonvulsants, gabapentin, and pregabalin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Visceral Pain Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on visceral pain market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for visceral pain ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The visceral pain market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Calcium Channel Blockers; Nonsteroidal Anti-Inflammatory (NSAID); Other Drug Classes
2) By Indications: Interstitial Cystitis; Crohn's; Irritable Bowel; Chronic Prostatitis; Other Indications
3) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Calcium Channel Blockers: Dihydropyridines; Non-Dihydropyridines
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Visceral Pain Market Characteristics
3. Visceral Pain Market Trends And Strategies
4. Visceral Pain Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Visceral Pain Growth Analysis And Strategic Analysis Framework
5.1. Global Visceral Pain PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Visceral Pain Market Growth Rate Analysis
5.4. Global Visceral Pain Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Visceral Pain Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Visceral Pain Total Addressable Market (TAM)
6. Visceral Pain Market Segmentation
6.1. Global Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Calcium Channel Blockers
Nonsteroidal Anti-Inflammatory (NSAID)
Other Drug Classes
6.2. Global Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interstitial Cystitis
Crohn's
Irritable Bowel
Chronic Prostatitis
Other Indications
6.3. Global Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users
6.4. Global Visceral Pain Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dihydropyridines
Non-Dihydropyridines
6.5. Global Visceral Pain Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs (NSAID), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selective COX-2 Inhibitors
Non-Selective NSAIDs
6.6. Global Visceral Pain Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
